ArticleFrontiers in pharmacology2026
miRNA101a secreted by EATMs regulates atrial fibrillation through the PDGF-mediated PI3K/AKT pathway.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia worldwide, and microRNAs (miRNAs) are gaining significant attention in cardiovascular disease research. In this study, we explored the specific mechanisms by which miR101a contributes to the pathogenesis of AF, aiming to identify a novel biomarker for its early detection. Methods: In this study, we examined the differential expression of miR101a in human left atrial appendage tissue using RT-PCR. We developed a Sprague-Dawley rat model of AF and assessed the expression of associated phenotypic markers and proteins through flow cytometry, immunofluorescence, and Western blotting. Potential targets were identified via bioinformatics analysis and dual luciferase assay. We modulated miR101a expression using adenoviral transfection to elucidate its regulatory mechanism in AF. This approach allowed us to identify and validate the pathway through which miR101a influences AF. Results: The experimental results indicated that miR101a was highly expressed in the sinus rhythm group of patients and played a crucial role in the myofibrosis associated with AF. miR101a interacted with PDGF-DD, contributing to fibroblast fibrosis, and modulated the fibrotic process by promoting the degradation of collagen and extracellular matrix in AF. Conclusion: In this study, we demonstrated that miR101a, secreted by epicardial adipose macrophage-derived exosomes, regulates AF via the PI3K-Akt pathway and by targeting PDGF-DD. These findings suggest that miR101a holds promise as a novel biomarker for AF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.